Pan-cancer analysis of the TRAF family genes and their correlation with prognosis, TME, immune and drug sensitivity

• Published in: European journal of medical research 2024-06, Vol.29 (1), p.307-307, Article 307
• Main Authors: Yao, Bin, Hu, Weikang, Chen, Yu, Li, Jing, Jiang, Kuirong, Dou, Jin
• Format: Article
• Language: English
• Subjects: Biomarkers, Tumor - genetics; Cancer; Cancer prognosis; Computational Biology - methods; Development and progression; Drug Resistance, Neoplasm - genetics; Drug sensitivity; Gene Expression Regulation, Neoplastic; Genes; Genetic aspects; Humans; Immune; Immune response; Ligases; Metastasis; Neoplasms - drug therapy; Neoplasms - genetics; Oncology, Experimental; Pan-cancer analysis; Prognosis; Tumor microenvironment (TME); Tumor Microenvironment - genetics; Tumor Microenvironment - immunology; Tumor necrosis factor; Tumor necrosis factor receptor-associated factors (TRAFs); Tumor Necrosis Factor Receptor-Associated Peptides and Proteins - genetics; Ubiquitin
• ISSN: 2047-783X; 0949-2321; 2047-783X
• DOI: 10.1186/s40001-024-01875-8

Tumor necrosis factor receptor-associated factors family genes play a pivotal role in tumorigenesis and metastasis, functioning as adapters or E3 ubiquitin ligases across various signaling pathways. To date, limited research has explored the association between tumor necrosis factor receptor-associated factors family genes and the clinicopathological characteristics of tumors, immunity, and the tumor microenvironment (TME). This comprehensive study investigates the relationship between tumor necrosis factor receptor-associated factors family and prognosis, TME, immune response, and drug sensitivity in a pan-cancer context. Utilizing current public databases, this study examines the expression levels and prognostic significance of tumor necrosis factor receptor-associated factors family genes in a pan-cancer context through bioinformatic analysis. In addition, it investigates the correlation between tumor necrosis factor receptor-associated factors expression and various factors, including the TME, immune subtypes, stemness scores, and drug sensitivity in pan-cancer. Elevated expression levels of tumor necrosis factor receptor-associated factor 2, 3, 4, and 7 were observed across various cancer types. Patients exhibiting high expression of these genes generally faced a worse prognosis. Furthermore, a significant correlation was noted between the expression of tumor necrosis factor receptor-associated factors family genes and multiple dimensions of the TME, immune subtypes, and drug sensitivity.